Vext Science, Inc. ($VEXT)

Earnings Call Transcript · April 29, 2026

CNSX CA Health Care Pharmaceuticals Earnings Calls 46 min

Earnings Call Speaker Segments

Operator

Operator
#1

Thank you for standing by. This is the conference operator. Welcome to the Vext Science First Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] The conference is being recorded. [Operator Instructions] I would now like to turn the conference over to Priam Chakraborty. Please go ahead.

Unknown Executive

Executives
#2

Thanks, operator. Good morning, everyone, and thank you for joining us today. Vext's fourth quarter and fiscal year 2025 financial results were released earlier this morning. The press release, financial statements and MD&A are available on SEDAR+ as well as on the Vext website at vextscience.com. We would like to remind listeners that portions of today's discussion include forward-looking statements and that forward-looking statements are included in today's filings. There can be no assurance that these forward-looking statements will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results contained therein will materialize. Risks and uncertainties that could affect future developments, circumstances or results are detailed in the MD&A and Vext's other public filings that are made available on SEDAR+, and we encourage listeners to read those risk factors in conjunction with today's call. As a result of these risks and uncertainties, the developments, circumstances or results predicted in forward-looking statements may differ materially from actual developments, circumstances or results. This call also includes non-IFRS financial information, and such non-IFRS financial measures are subject to disclosure and reconciliation included in our press release disseminated earlier today as well as the MD&A. Forward-looking statements made during this conference call are made as of the date of this call. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law. Vext's financial statements are presented in U.S. dollars and the results discussed during this call are in U.S. dollars. I will now pass the call over to Eric Offenberger, Chief Executive Officer of Vext.

Eric Offenberger

Executives
#3

Thanks, Priam. Good morning, everybody, and thank you for joining our fourth quarter and fiscal year 2025 financial results conference call. I'm joined today by Trevor Smith, Vext's CFO. 2025 was a year of solid execution and meaningful transition for Vext. We made important progress across both of our core markets while continuing to build and organize the business for the next phase of growth, the key takeaway from the quarter and the year that our strategy is working. As we said consistently, our focus on owned retail gives us greater control over the customer experience and supports cash flow generation over time. We've been focused on building a retail-led platform. And in 2025, that focus translated into strong revenue growth, improving cash generation and record operating cash flow. In the fourth quarter, revenue was $13.7 million, up 35% year-over-year, with operating cash flow of $3.2 million, driven by continued strength in Ohio. For the full year, revenue grew 43% year-over-year to $51.4 million, and we generated $11.7 million in operating cash flow, up 256% year-over-year. I want to address Q4 EBITDA directly. Reported Q4 EBITDA was negative $3 million, reflecting a $5 million noncash impairment on one of our Columbus, Ohio dispensaries. The impairment is primarily driven by revised cash flow expectations following significant growth in competing dispensary counts in the Columbus market since our original acquisition and not by the store's operating performance, which remains at the state per store average. Excluding the impairment, Q4 adjusted EBITDA was $2.1 million. The underlying performance of the business remains strong and continues to reflect the effectiveness of our retail strategy. What stands out to me is that we delivered this performance while operating across 2 very different markets. Navigating both with discipline isn't easy, and I'm very pleased with how our team executed across both this year. Turning first to Ohio. Ohio continues to be the primary growth engine for Vext and a key driver of our financial performance. 2025 marked the first full year of the adult-use market in the state with total cannabis sales exceeding $1 billion statewide. While the competitive landscape expanded meaningfully with the number of licensed dispensaries increasing by nearly 50% over the course of the year, Ohio remains a highly controlled and structurally defensible market with a capped retail model, disciplined rollout of new stores and regulatory safeguards that support long-term pricing and margin stability. Within this framework, we continue to see a clear opportunity to scale our presence with high-quality retail locations. We made significant progress expanding our retail footprint in 2025, growing our Ohio retail presence from 2 stores to 5 operational locations. During the year, our Ohio retail operations accounted for over half of consolidated revenue with sales increasing over 120% year-over-year. The majority of our stores performed at or above the statewide per store average. Looking ahead, our focus is on completing our build-out to the 8-store license cap. We expect to open our sixth location in the second quarter of 2026. We are particularly excited about this Fairfield location, which is positioned in a high visibility quarter and includes a drive-thru format that has already been well received at some of our other stores. We expect Fairfield to ramp efficiently and become a meaningful contributor to revenue and cash flow as it stabilizes. Beyond that, our seventh location is currently under construction and expected to be operational by the end of 2026 with an eighth and final location anticipated to open in early 2027. As these additional doors come online, we expect them to further support revenue growth, operating leverage and cash flow generation across the Ohio platform. As we complete the Ohio retail expansion, we are actively redeploying capital toward vertical integration and cultivation expansion to support that network. This includes advancing plans to expand cultivation capacity at our Jackson facility and further develop our manufacturing capabilities. Overall, we believe Ohio provides a clear path to scale within our existing license structure. Turning to Arizona. Arizona remains a mature and competitive market with continued pricing pressure driven by excess supply. In fiscal 2025, total cannabis sales in the state declined approximately 3%, while average item prices were down 7% to 8% year-over-year. Despite this backdrop, our performance remained resilient. Our retail locations performed above the statewide per store average for most of the year, supported by strong cultivation yields and disciplined execution across the business. That said, the fundamental economics in the Arizona cultivation market are clear, and we are taking decisive action. As announced in March, we are transitioning to a lean retail-first model in Arizona. This includes exiting cultivation through the shutdown and decommissioning of the Eloy facility during the second quarter of 2026. The property will then be marketed for sale with proceeds expected to reduce debt and further strengthen the balance sheet. Third-party supply will begin replacing Eloy output in the middle of the second quarter with the full transition reflected in the third quarter, which is a seasonally slower period in Arizona and aligns well with the timing of this shift. We expect that this shift will remove the internal sell-through constraints that impacted pricing and product mix in 2025. Going forward, Arizona will be focused on maximizing performance at our 2 Phoenix area dispensaries while expanding our manufacturing and distribution capabilities through a more capital-light model, including third-party distribution and contract manufacturing. Arizona will be operated with a focus on cash generation and margin optimization rather than capacity investment. We also continue to evaluate disciplined M&A opportunities with a focus on strengthening our position in core markets and maintaining flexibility to pursue opportunities that meet our return thresholds. As we look ahead to 2026, we are entering the year with a more focused footprint and a clear capital allocation framework. Our priorities are straightforward: completing the Ohio retail build-out, expanding cultivation capacity to support that network and continuing to optimize our Arizona operations with capital directed toward our highest return opportunities, we expect to drive continued margin expansion, strong cash flow generation and long-term shareholder value. Before I close my remarks, I would like to note last week's announcement from the DEA regarding the reclassification of state licensed medical cannabis at the federal level. While still early, this represents a constructive step that could support both efficiency and better access to financing for solid players in the industry while further aligning federal policy with the framework already established across many states. Our view internally is that it will continue to be a state-by-state market, but this news was a long time coming and a step in the right direction. With that, I'll turn it over to Trevor for a closer look at the financials. Trevor?

Trevor Smith

Executives
#4

Thank you very much, Eric. Overall, 2025 was a year of strong financial performance for Vext, marked by meaningful revenue growth and a significant step-up in operating cash flow as the business scaled. Starting with the fourth quarter. Revenue was $13.7 million, up 35% year-over-year and up 8% sequentially, reflecting continued contribution from our expanded Ohio retail footprint. Operating cash flow was $3.2 million, an increase of $1.9 million sequentially, with cash flow margin improving to 23%. This reflects strong underlying performance and improved conversion of earnings into cash as the business scales. Adjusted EBITDA in Q4 was $2.1 million, reflecting inventory accounting impacts related to pricing pressure, particularly in Arizona, which are expected to normalize as that inventory turns. Operating cash flow provides a clearer view of the underlying performance for the quarter. Turning to the full year 2025. Revenue was $51.4 million, up 43% year-over-year. Growth was primarily driven by Ohio, including the consolidation of 3 additional dispensaries and the first full year of adult-use sales, which more than offset pricing pressure in Arizona. EBITDA was $5 million for the year, representing an increase of $7.2 million year-over-year and a return to positive EBITDA. Adjusted EBITDA was $10.9 million, up approximately 21% year-over-year. The 2025 annual adjusted EBITDA margin was also 21% compared to 25% in the prior year. The year-over-year decline in adjusted EBITDA margin primarily reflects pricing compression in Arizona, which reinforced our decision to exit cultivation in that market to focus on retail. Operating cash flow was $11.7 million, up 256% year-over-year. The 2025 cash flow margin also improved to 23% of revenue compared to only 9% in the prior year. The increase in cash flow margin reflects the shift towards a greater mix of retail sales, disciplined cost management, improved cultivation yields and improving operating leverage as the platform scaled. There are a few items worth highlighting to help frame these results. In the fourth quarter, we recorded a $5 million impairment related to our Columbus, Ohio dispensary, including $3 million of goodwill and $2 million of intangibles. This reflects the balance sheet valuation adjustment and not the store's underlying operating performance, which remains at the state average. We also recorded an increase in our uncertain tax position to approximately $8.1 million at year-end, following a restatement of prior periods to reflect previously understated balances. This resulted in the recognition of a UTP liability of approximately $5.5 million as of January 1, 2024, and a $7.7 million as of December 31, 2024, including the reclassification of approximately $5.3 million from income taxes payable and accrued liabilities with a net incremental liability of $2.4 million recorded through opening retained earnings. I would like to highlight that this was a balance sheet-only adjustment with no impact on cash, revenue, gross profit, net loss or earnings per share for any period. The increase reflects updated estimates of potential interest on certain tax periods and resulted in higher interest expense in Q4 2025. We note these items remained under audit and subject to change. As Eric outlined, the DEA issued a final rule to reschedule certain state-licensed cannabis products to Schedule III on April 23, which included a recommendation for retroactive tax treatment under Section 280E. For context, Arizona operated as a medical-only market through 2020 and Ohio was medical only through the third quarter of 2024. If enacted, we believe a substantial portion of the periods reflected in our own uncertain tax position would fall under the medical use window and the recommended retroactive relief could result in a material reduction in the liability over time. The company will recognize any financial impacts of this rule, including any retroactive relief when the tax authorities enact or clarify the recommendation by the DEA. No financial impact from this rule was recognized in the 2025 statements. Additionally, we made certain classification updates between cost of goods sold and operating expenses in consultation with our auditors and advisers. These changes have no impact on prior period results and comparative figures remain unchanged. Taken together, these items are primarily nonoperating and do not impact our view of the underlying financial performance of the business. Operating expenses increased approximately 31% year-over-year, primarily as a result of the previously mentioned $5 million impairment related to the Columbus, Ohio dispensary. Excluding that onetime event, operating expenses were relatively stable and actually declined as a percentage of revenue. On the balance sheet, we ended the year with approximately $5.1 million in cash and continue to reduce debt during the period, reflecting our focus on strengthening the balance sheet through ongoing cash generation. Reported working capital at December 31, 2025, was negative, primarily driven by the $8.1 million uncertain tax position I just mentioned. IFRS requires this item to be classified as current, even though the timing of repayment is uncertain, particularly in light of the previously mentioned DEA rule. Overall, the business continues to perform well. We are scaling our retail platform, beginning to see operating leverage and generating strong and consistent cash flow. With a more focused operating structure and capital directed towards our highest return opportunities, we believe we are well positioned to continue driving these metrics higher in 2026. Thank you, everyone, for joining us for our fourth quarter and fiscal year 2025 financial results conference call. I'll now turn it over to the operator for your questions.

Operator

Operator
#5

[Operator Instructions] The first question today comes from Pablo Zuanic with Zuanic & Associates.

Pablo Zuanic

Analysts
#6

Congratulations on the free cash flow performance. I think that on market cap, that's about a 15% free cash flow yield. I mean that's a very attractive number. Look, on the retail front in Ohio, I have 2 questions. One, more macro about the market. Yes, we are seeing this growth in the number of stores that's ahead of the actual market growth in terms of sales. But that seems to be a bigger deal in the bigger cities than in the more, call it, rural areas or smaller towns. And please correct me if I'm wrong, but I see you're taking this write-down on the Columbus store, but you're not adjusting or doing write-downs on your other 4 stores, right? So that's the first question more at a macro level. And then the second question, if you can just give more of an update on your 5 stores in terms of their competitive position. I know you're talking about you're performing in line or above the market average in terms of revenue per store. But as we know, that market average has been coming down, right, but your retail sales were up. So I guess they are outperforming. But if you can just give more color about the 5 stores in terms of competitive landscape.

Eric Offenberger

Executives
#7

Yes. Let me try to frame that a little bit for you, Pablo. So for us, the Columbus store is the one that had the biggest competitive thing. I think your assessment of the market is correct. That's where people tend to gravitate towards. And obviously, the stores that are not in those situations are not getting the competitive pressure, and we don't have any impairment related to it period. The other thing it also is the Columbus store was something we didn't buy as part of a normal negotiation. It was part of the acquisition of the -- our partner buyout in Ohio. That was something negotiated quite a while ago before you started seeing the landscape. So I think that was part of it, too, as things develop, you get more clarity to it versus what it looked like 6 years ago type of thing. So I think that's also impacted the Columbus store. So we think that, that's going to continue to go and continue to develop. And those stores will get all built out and get caught up and everything starts to shift. So we've always been focused on, as we said, of selling our product through the stores. So we like the rural stores. We like those locations because it makes it a little bit easier for us to reflect solid market performance. So that's how I'd answer that question. I don't know if Trevor would give you any more color on the per store. But when we say in the reports that the majority of them are above state averages, the ones that are lower than state average, we still get a good return on our investment and return on assets is how we look at it. We don't really focus as much on the top line. We know that the market likes to look at that. We look at what cash we're generating through the store and what profit.

Pablo Zuanic

Analysts
#8

Okay. And then just a follow-up on the 3 next stores to open. I know you said Fairfield in the second quarter sometime that was supposed to have opened, I think, in the fourth quarter last year. If you can just give more color about the delays there. And then on stores #7 and 8, that's Columbus and Cincinnati. I mean, traditionally, you focus again more in the smaller towns, rural areas, right? And you're seeing more competition on the bigger cities. So should we be concerned about store #7, #8? And is there room or leeway to relocate those stores?

Eric Offenberger

Executives
#9

Okay. So the issue with the store in Cincinnati that we did plan on opening in the late year is candidly, I didn't realize that asphalt companies close in Ohio during the winter and you can't pour asphalt. And that's really the delay there is we're still getting pavement put in, in the asphalt laid down in that location. So you're very weather dependent on that. So that's what's been the biggest delay there. The store is ready to go. Everything is in. We cannot call for inspection from the state until we have the certificate of occupancy. And we cannot get the certificate of occupancy until the paving is done. They've been working on it, finishing it. We expect in the next couple of weeks, that will be done, and we can call for the state inspection. That store, based upon where it's located, it's in a prime area as we've talked about and has a lot of traffic area. So when we're looking at a major -- being in a bigger market like we talked about, if we're locating the store, not something we bought, we look at what the traffic patterns look at, what the surrounding areas look like and if they are preventing dispensaries from going in. So on Columbus, that's what we're doing on the second store. It's right off of a major belt on the freeway. It's in a good community area and one of the townships right next to it has got a moratorium on dispensaries. So those people are traveling, we're going to be a convenient travel for them. And as I said, it's off of the beltway. In that city, it will have a drive-thru access to it, something we couldn't do on our existing Columbus store, that wouldn't work. Same thing on the second Cincinnati store. Depending on what the zoning looks like, it potentially could be adjacent to our retail similar in Cincinnati now with the large retail chain that we're working with there. So we're trying to see if we can't put another store on that existing property or the other community that we're looking at and working with, trying to get through zoning there has been the challenge. It's on a major throw fare and has good traffic access, a good pattern, and they've limited their license. So when you say Cincinnati, it's really like a suburb of Cincinnati. So we think those 2 stores are going to perform well, depending on where they go within those 3 locations.

Pablo Zuanic

Analysts
#10

Let me just add a couple of more, if I may. One, just bigger picture regarding Ohio. I think in the third quarter last year, pre-rolls were allowed, right? And I think the purchasing limit per consumer was also increased. Have we seen a pickup in the market? And I guess to some extent, we're still awaiting the adult-use rules, right? It's still called on medical. If you can just give some more color in terms of a bigger picture in Ohio in that way. I'll follow up with another one.

Eric Offenberger

Executives
#11

Yes. I think you got some clarity on some of that stuff, too. Surprisingly, the pre-rolls haven't taken off for us like they have in other markets. People are still buying the flower. And that realm edibles still do well in Ohio comparative to like Arizona for us as a percentage. So different methods of consumption. As far as the rules, I think there's got a lot of clarity coming out. The state has got some new rules coming in with labeling and stuff along those lines that take effect all the way in September, changing how you do the product setup and some clarity there. So we're still seeing that and they're changing some of the dosing that you can buy on adult use and what the quantities are. We're now doing 8th in that market instead of the 10th like we were doing in that market. So that's been a switchover for us, which has been nice to get that. So it's a little bit easier on the business. So some of those things are coming in. They've leased lighten up the advertising a little bit. We can put a sign up on the store, that type of stuff. And we're doing all those things. The biggest thing we're doing in Ohio, Pablo and the existing stores is getting the drive-thrus into them where we can. So the Jeffersonville stores drive-thru should be opening any day. The Athens store is under construction. We hope to have that open in a few -- in the next month. And we think that's really the key is that convenience of topping that consumer in and out of that store as quick as we can and allowing the delivery method for them to be more traditional.

Pablo Zuanic

Analysts
#12

And one very last one. I mean, obviously, we only had the final order from the DOJ just come out last week, right? So I know it's too early to tell a lot of things. But in your opinion, are M&A discussions picking up or no change? And I'm referring to the comment you made, right, that you may look at more stores in Arizona and perhaps entering other states or even Vext partnering with another company in some form of merger. But what color can you share about your expectations about how M&A plays out given all this positive backdrop on the regulatory front at a federal level, national level?

Eric Offenberger

Executives
#13

I think that a lot of places, a lot of people have these uncertain tax provisions and stuff along those lines and you look at some of the concentration of states that they were selling into. So if that Department of Justice recommendation into treasury becomes law, and retroactive, then you're going to have a lot of people sitting with a lot of cash on their balance sheet. And I'm sure that they'll start looking at ways to deploy it. What I think will be different, though, on this one, Pablo, is that people will be looking not at unreasonable multiples and be looking at more of operational type of things versus in the past where they were trying to scale up to size and top line, they'll be looking at where contribution can be and how much are you going to take on a drag of past, as I'd call them, on their balance sheets of what they're acquiring. So I think you'll see some of that. That would be a natural to me. I think it will take a little bit of clarity. I don't think anybody is going to want to jump out and say, okay, we're going to get retroactive without the IRS saying that. So I think that's one issue. I think from our perspective, and again, who knows. But Trevor and I, as we talked in the past, we're actively doing audits with the IRS on our stuff and have audits open through 2023 as we've disclosed previously and talked about. Those are always a negotiation and going back and forth of what's allowable, what's not allowable. And it's a long process. We're hoping that there will be more clarity to the process and that the agents will start to get some clarity internally. So it's not like consistently renegotiating. We're dealing right now with 3 or 4 different agents on the same files because they switch off and stuff like that. So that's where you get some of this inconsistency and that's really challenging. As Trevor mentioned in our notes, that's why we end up with having to do a restatement and stuff along those lines as we get more clarity as we go. Hopefully, this will help with that, too. So I see that's a real positive. I see the other side on that as a positive. And absolutely, you'll see more M&A activity. And whether you are acquiring, merging or doing whatever, you say there's going to be more capital available, and it will be a different look this time. I think it will be more accretive to the shareholder and not this large buy at all cost type of thing.

Operator

Operator
#14

The next question comes from Paul Penney with Partner Capital Group.

Unknown Analyst

Analysts
#15

With the cultivation like strategy in Arizona, what are your long-term and near-term margin expectations? And specifically, like what is your average cost to produce these days per pound and compare that directly with what is third-party biomass spot prices and so forth? What's that variance or margin today?

Eric Offenberger

Executives
#16

Well, without giving you specific numbers because we don't really do that and haven't historically done that. As Trevor has mentioned, the -- and Trevor and the team have done a really good job on this. I want to make sure everybody understands what happened in Arizona. So the yields continue to go up. The quality continued to go up. They were really doing a great job, and that's really held our -- held us into this position for where we were for the last couple of years as we watch the market continue to decline in Arizona. We really didn't expect it would continue to decline, but it did. So as it declined, we're producing at about what we would consider like an average indoor grow cost somewhere in the mid-300s. I think that's pretty realistic across the market in that. And then once you do it all baked in on a return on investment and stuff like that, you're in the $800 range to $850, $900 depending on how your cost of capital is as a company. I think that's pretty realistic. And I think anybody telling you different, I'd like to see their books. So that seems to be where that falls into place. So what happens is in the marketplace like Arizona with the overhang, it's a typical supply-demand thing. On the wholesale thing, they're trying to move volume. So there's people trying to make payroll and they will discount basically to cash or below cash, recuperating costs that are 5 months old in what they spend on cash. So from our perspective, that marketplace tells you that you don't really want to be in that production thing as it's going through its process and the way we structure our asset base, it's more lucrative for us to redeploy that capital. So that was the decision that was made on that. And again, it's not a reflection on what the quality was or the cultivation. It's a reflection on the market. So we go to market believing we don't set the market. We participate in it. So we look at what's the opportunity in the market and where can we fit in. So that's where we fit in. You basically have to get out of the cultivation business.

Unknown Analyst

Analysts
#17

That's great. I understand. And then are there any interesting dispensary acquisitions out there that make any economic viability? I know expectations have been lofty in the state despite the challenges. Are you seeing any change there?

Eric Offenberger

Executives
#18

Not really. I mean I think the value of the license is still really there. And candidly, Paul, as you look at it and if you're X and you look at your value of your license, we've always said that the cultivation is almost like a negative. So it's a drag. So let's say, your cultivation license or your dispensary license is worth X, if you have a cultivation, it's X minus Y. So you really have to deal with that cultivation to unlock your value as that market consolidates because supply is out there. So if you're an acquirer, why would you want to do that, have extra supply. Now you have to deal with it and what the liquidation is and everything like that. Fortunately, the way we've done our assets, we're going to deal with our cultivation. So we think that, that should give us a premium on what happens in Arizona, and we're pretty optimistic that our results from Arizona go up both on an EBITDA basis and on a cash flow basis. So that's kind of our impression. We become a lot more nimble in the market and a lot more flexible. And if you're not going to have tremendous scale, you better be damn nimble or you're not going to survive it. So that would be my color. I think Trevor has got some color on that, too. I'd like his input on this question.

Trevor Smith

Executives
#19

Yes, the decision to close Eloy was not an easy one. The team did just such a hell of a job performing and improving performance over time, and we saw even a pathway to continue to make some capital-light investments to further improve performance. But at the end of the day, the macro is too much to ignore and the redeployment of capital into more accretive opportunities, particularly as Ohio continues to scale and expand as we've disclosed. It was just too much for us to ignore. And so that's why the decision was made.

Unknown Analyst

Analysts
#20

Very smart actually. And then just a couple of house cleaning items in Ohio. Do you expect any other impairments, just to be clear, in the state? And then secondly, of the 8 stores, how many do you expect will have drive-thrus?

Trevor Smith

Executives
#21

No. So to be totally clear, as we mentioned in the filings, no additional impairment is expected in Ohio or any other location. This includes the Arizona licenses. No impairment was taken on Eloy. We'll have more updates as that sale process continues, but no reason to expect any impairment there. I believe the drive-thru number, only the Columbus store that we took the impairment on is not able to have a drive-thru, which is certainly impacting the future cash flow forecast from when it was originally acquired and perhaps the driving force towards the impairment we took in Q4.

Operator

Operator
#22

[Operator Instructions] The next question comes from Josh Felker with CB1 Capital.

Unknown Analyst

Analysts
#23

Congrats on your strong performance there. A few questions. I'll stick with Ohio to start. You mentioned last quarter a few ongoing pilot programs to boost operating efficiencies. Just wondering when will we know the results of those programs? And do you now have any clear line of sight on potential benefits derived from those programs yet?

Eric Offenberger

Executives
#24

Trevor, that's probably yours.

Trevor Smith

Executives
#25

Yes. So we mentioned the sharp improvement in yield. I think you saw that in the Note 6 of the financial statements and the biological assets. We disclosed grams per plant. That went up significantly in Q4. We're happy to report it went up again high single digits again in Q1, and we're expecting further increase in yield is going to be the biggest driver. So that is going to fuel supply in the market and any potential weakness from additional stores opening before we can get ours open, it's going to be offset by additional wholesale because Ohio is very much the cultivation-led business with trying to pair to retail. Anytime cultivation gets ahead of retail, we have that wholesale channel to offload and then obviously, we want to get our own retail back in to recover that additional supply. So I'd say that's the biggest one. And then the other pilot programs to drive performance in Ohio are certainly going to be those drive-thrus. So really excited about the Athens drive-thru in particular, as well as the drive-thru in the new Fairfield location once it gets open. Those are 2 Athens already is a great performer and then Fairfield is expected to be great even ahead of that. So we think those, in addition to cultivation yields are going to be the biggest performers for Ohio in '26.

Unknown Analyst

Analysts
#26

So fair to assume a little less than a pilot program, a little more of an operating strategy that you've already cleared and they've already approved of. Understood. Trying to break down Ohio revenue composition going forward, as you just noted, Trevor, obviously, the wholesale market is going to be a larger part until those stores come online. You noted last quarter, the increase in Ohio supply will boost wholesale sales until your new stores come online. Just interested in what percentage of the existing facility is sold into the wholesale market today. And then with the Jackson expansion plan, I'm just wondering, once that's fully online, how much additional capacity do you think you will possess beyond what you will require to service your own doors?

Eric Offenberger

Executives
#27

It's a give and take. I think it's a dodger question. I'll give you a straight answer, but it's -- there's a lot of assumptions. How quickly does the yield come up, how quickly do the stores come up. Our view is we always are going to try to maximize that yield. As the yield comes down, we look for the distribution internally, how the store is doing, the drive-thrus, the new stores. So it's something we actually, as a leadership team, stay on very, very close and make quick decisions, but certainly as close to real-time decisions on pricing and availability for wholesale as many times as we can for the state of Ohio. So it's going to be a give and take through '26. The additional expansion plans also need to be approved by the state. So I'll wait to comment on additional capacity, but we certainly have line of sight into continued growth in that market. And our overall strategy of trying to stay 70%, 80% vertical has not changed.

Unknown Analyst

Analysts
#28

Just interested in how no cultivation impacts Arizona's strategy. I know you still have the manufacturing operations outside of Eloy. So it still sounds like you'll run those operations, and it still sounds like you'll service those manufacturing device segments. Just wondering, is all of that correct? And those segments are typically higher margin versus flower fuming segments. Am I correct in that understanding for Arizona?

Eric Offenberger

Executives
#29

Yes, Josh, yes, I think you're clear on that. So really, the manufacturing that we're doing in Arizona is we have some relationships with people that we do manufacturing for, and I think we'll continue to do that. And it's just a real light and light touch. So the expense structure is not that heavy on it. And it kind of gives you the insurance on the back end if cultivation was to change, we do have some cultivation asset in that area that could match demand in those stores if we needed it. So if there was a fire or some natural disaster, we could stand up cultivation relatively quick and not have a heavy cost structure. So it was more of the insurance to it, too. So that said, but we're going to be in a market. So the way we really look at it, Josh, is we think that the space that you have to look at in this industry is not necessarily marketing but merchandising. So you're really merchandising your product. It's not like I'm trying to create a demand. I'm trying to move that demand through a retail channel as quick as I can as efficiently as I can and you line up your manufacturing to back it. So that's why we don't see it like we're trying to entice somebody to use cannabis as far as your marketing. You're more in trying to merchandise it like traditional consumer products or something along those lines. And then we think there's a distinction, and that's really the way we try to go to market on the retail side. So with that said, that's why we looked and said, okay, the manufacturing makes sense because we're really doing a contract on the OEM side and white label, and we do that efficiently, and there's a need in the marketplace because there's so much capacity on the cultivation side that it will line up and you've got your retail store, you can do some of that through, plus you have the alignment and now you switch too, because you become more of a shelf space for somebody that doesn't have that distribution channel. So you can really line it up. So we think it's going to be significantly improved for our position and for our consumer base when we're merchandising to them and gives us a lot more flexibility. That would be my comments. I think Trevor might have some other color on it, but...

Trevor Smith

Executives
#30

Yes. Just to clarify, Josh, manufacturing is in a facility in Phoenix. So it will not be impacted by the Eloy closure other than obviously, a trim being produced at that facility won't be available for processing. But fact you're closing a facility due to oversupply tells you we're not concerned about acquiring input material for the manufacturing team.

Unknown Analyst

Analysts
#31

And apologies, if I'm going to sneak in a third question. I'm just wondering how large is the competitive advantage for drive-thrus in Ohio? Are competing dispensaries around you also equipped with drive-thrus? Or do you think you'll be able to capture some of those consumers by having that offering when other dispensaries do?

Eric Offenberger

Executives
#32

The Columbus one on the main drive, the competing dispensaries that are really close to it, one of them has a drive-thru, a couple of the others don't. So you're kind of in a residential area and all street parking of pain, that kind of stuff is the problem with that one, Josh, and you can't really fit it in. If you could send stuff through a pneumatic tube or something along those lines, you can probably get a right way with it like a bank. but that's not allowed at this point in time. So you really can't configure it. The other stores right now are more of the rural stores, and it's a big benefit. But it's not a benefit because competition is there, doesn't have them. You have less competition and less density, right? So it's more of -- you're hitting somebody with the convenience factor and stuff along those lines. In Arizona, we did that with like walk-up windows inside of the dispensary. So you're technically getting your cannabis in the dispensary, but you're really going through a window so you can bypass the reception, can bypass all that check in, like the [ speedy window or speedy weedy ], that type of concept. Then when you get to Ohio, we think the drive-thrus really are big. When we get to Cincinnati, we see that's going to be really big because as Trevor has mentioned before, the unique part of that store right now is it's at a large area with a lot of traffic, and we're in an area where there's a large box anchor that sees a lot of traffic. So we think just by geographics and being close to it, if you have a convenient in and out way, you get that convenience purchase. And we think that's a good purchase to have, and that's an easy way to get those people passing through that drive-thru.

Operator

Operator
#33

This concludes the question-and-answer session and today's conference call. You may disconnect your lines. Thank you for participating, and have a pleasant day.

For developers and AI pipelines

Programmatic access to Vext Science, Inc. earnings transcripts and 32,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.